Mapp Gets U.S. Funds To Develop Ebola Drug | Chemical & Engineering News
Volume 92 Issue 36 | p. 14 | Concentrates
Issue Date: September 8, 2014

Mapp Gets U.S. Funds To Develop Ebola Drug

Department: Business
Keywords: Ebola, monoclonal antibody, Health & Human Services

The Department of Health & Human Services has signed a $24.9 million, 18-month contract with Mapp Biopharmaceutical to support the development and manufacturing of ZMapp, an experimental drug that has been given to some Ebola patients. Under the contract, Mapp will manufacture a small amount of the drug to demonstrate safety and efficacy in humans. Mapp will also work with HHS’s Biomedical Advanced Research & Development Authority to improve the manufacturing process for the drug, which is a combination of three monoclonal antibodies grown in tobacco plants. It is currently in extremely short supply.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment